International Stem Cell Corp (ISCO) Stock Price & Analysis
International Stem Cell Corp (ISCO) rose 0.00% to USD 0.17 as of June 10, 2026 at 03:42 UTC, according to Nexqual real-time market data.
ISCO last closed at USD 0.17; the session ranged USD 0.17–0.17 on volume of 4 shares. Market capitalization is $1.36M, with a 52-week range of USD 0.11–0.27 (OQB). Source: Nexqual, June 10, 2026 at 03:42 UTC.
Key Statistics (as of June 10, 2026 at 03:42 UTC)
| Price | USD 0.17 |
|---|---|
| Change | ▲ 0.00% (up) |
| Previous Close | USD 0.17 |
| Open | USD 0.17 |
| Day Range | USD 0.17 – 0.17 |
| 52-Week Range | USD 0.11 – 0.27 |
| Volume | 4 shares |
| Market Cap | $1.36M |
| Exchange | OQB |
Technical Analysis (ISCO)
Nexqual's technical model rates ISCO "STRONG BUY" based on 5 bullish and 0 bearish signals across 123 daily candles, as of June 10, 2026 at 03:42 UTC.
| Overall Signal | STRONG BUY |
|---|---|
| RSI (14) | 54.22 (neutral) |
| vs SMA50 | Above (USD 0.17) |
| MACD | 0 (positive) |
Analyst Ratings (ISCO)
Wall Street analysts rate ISCO "None", per Nexqual as of June 10, 2026 at 03:42 UTC.
| Consensus Rating | None |
|---|
Earnings (ISCO)
Source: Nexqual, June 10, 2026 at 03:42 UTC.
Financials & Fundamentals (ISCO)
| Total Revenue | $9.29M |
|---|---|
| Revenue Growth (YoY) | +8.70% |
| Gross Margin | +56.98% |
| Operating Margin | -8.21% |
| Profit Margin | -4.11% |
| ROE | -256.38% |
| Debt / Equity | 4,190.48 |
| Current Ratio | 0.76 |
| Total Cash | $933,000 |
| Total Debt | $3.52M |
| Free Cash Flow | $-106,875 |
Source: Nexqual, June 10, 2026 at 03:42 UTC.
Financial Health Score (ISCO)
Nexqual rates International Stem Cell Corp's overall financial health "Critical" across five dimensions, as of June 10, 2026 at 03:42 UTC.
| Growth | Critical — Revenue -15% YoY (annual), sharp decline |
|---|---|
| Profitability | Weak — Not yet profitable — scaling phase |
| Balance Sheet | Critical — $933K cash vs $4M debt |
| Cash Flow | Weak — FCF negative: -$107K, burning cash |
| Efficiency | Critical — ROE -256%, ROA -2.8% |
Ownership (ISCO)
| Insider Ownership | +53.77% |
|---|---|
| Institutional Ownership | +0.00% |
| Shares Outstanding | 8.00M |
| Float | 3.70M |
Source: Nexqual, June 10, 2026 at 03:42 UTC.
Leadership (ISCO)
International Stem Cell Corp is led by Andrey Semechkin (age 65), Co-Chairman of the Board & CEO, per Nexqual as of June 10, 2026 at 03:42 UTC.
| Co-Chairman of the Board & CEO | Andrey Semechkin (age 65) |
|---|---|
| Executive VP, Chief Scientific Officer, Principal Financial Officer & Director | Russell Kern (age 39) |
| President of Lifeline Cell Technology | Rebecca McGee |
From International Stem Cell Corp's Latest SEC 10-K Filing (filed 2026-03-30)
Key Strengths & Strategy (as disclosed to the SEC)
- International Stem Cell Corporation, a clinical stage biotechnology company, focuses on the development of therapeutic and biomedical products in the United States, Asia, Europe, and internationally.
- It develops ISC-hpNSC, a neural stem cell program that has completed the Phase I clinical trial for the treatment of Parkinson's disease, as well as for treating stroke, traumatic brain injury, and Alzheimer's disease.
- The company offers anti-aging skin care products, including ProPlus Advanced Defense Complex, ProPlus Advanced Recovery Complex, ProPlus Eye Firming Complex, ProPlus Neck Firming Complex, ProPlus Advanced Aqueous Treatment, ProPlus Collagen Booster, ProPlus Elastin Booster, and ProPlus Brightening Toner.
- In addition, it provides human cell culture products comprising human skin cells and reagents for the study of skin disease, toxicology, or wound healing; human cells from the heart and blood vessels, and reagents to study cardiovascular disease and cancer; human bronchial and tracheal cell lines for the study of toxicity, cystic fibrosis, asthma, and pathogenesis; and human mammary epithelial cell lines for the study of breast cancer, three dimensional culture, and carcinogen screening.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| BTIM | BOATIM INC | USD 0 | ▲ 0% |
| BTX | BlackRock Technology and Privat | USD 8.86 | ▲ 1.14% |
| MCET | MULTICELL TECHNOLOGIES INC | USD 0 | ▲ 0% |
| CCEL | Cryo-Cell International, Inc. | USD 3.45 | ▼ 1.43% |
| NNVC | NanoViricides, Inc. | USD 1.4 | ▲ 1.45% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 03:42 UTC. This page is informational and not investment advice.